 CAMBRIDGE, Mass., Sept. 08, 2022 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that it will host a virtual investor event to present interim data from the first-in-human clinical studies of NTLA-2002 and NTLA-2001 on September 16, 2022, at 8:00 a.m. ET. 